Skip to main content

Advertisement

Table 2 Patient characteristics

From: Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer

Breed Age (years) Body weight (kg) Clinical stage (TNM)ϕ Number of tumors Parturition ERα
Standard scheme (Dox)
Standard Poodle 12 6 III 2 0 Positive
Maltese bichon 9 9.9 III 7 2 Positive
Dachshund 13 6.6 III 4 2 Positive
Maltese bichon 7 6.6 III 5 0 Positive
Standard scheme (Dox + I2)
Rottweiler 8 38 III 1 2 Positive
Standard Poodle 12 5.8 II 5 0 Positive
Standard Poodle 10 3.8 III 5 0 Positive
Labrador Retriever 10 30 III 7 0 Positive
Standard Poodle 12 6.4 V 8 1 Positive
Standard Poodle 9 7 III 9 1 Positive
Modified scheme (Dox)
Cocker Spaniel 9 10.3 II 8 0 Positive
Mixed breed 6 4.2 II 2 0 Positive
Cocker Spaniel 8 13 I 6 3 Positive
Chihuahua 5 2.2 I 3 0 Positive
German Shepherd 7 30.1 III 7 0 Positive
Dalmatian 6 23 I 1 0 Positive
Modified scheme (Dox + I2)
Cocker Spaniel 10 16.8 III 1 0 Positive
Mixed breed 8 7.6 I 5 0 Positive
Standard Poodle 11 4.2 V 7 0 Positive
Cocker Spaniel 13 9.8 III 7 0 Positive
Fox terrier Toy 7 2.4 I 5 0 Positive
Standard Poodle 10 4.5 III 3 0 Positive
Cocker Spaniel 13 17.4 III 7 3 Positive
Standard Poodle 10 6 II 8 0 Positive
Standard Poodle 9 4.7 III 6 4 Positive
Chihuahua 5 3.8 III 5 0 Positive
Dachshund 10 5.2 III 5 1 Positive
  1. ϕ T – Primary tumor, N – Regional lymph nodes, M – Distant metastasis [28];
  2. Bold numbers, overweight animals (10–30% of standard weight)